Zydus Lifesciences’ shares fell 6% to Rs 1,109 after acquiring a 50% stake in Sterling Biotech for Rs 550 crore. Analysts maintain neutral ratings with target prices of Rs 1,020 and Rs 1,210.
Citi bullish on Indian equities, sees Nifty at 28,000 by end-2027
Citi Research projects that India’s benchmark Nifty 50 index could hit 28,000 points by the end of 2027. This forecast is based on strong earnings